Drug · CHEMBL1007
Comparisons in its trials12
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
1 to 12 of 12
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| BMI ≥30 kg/m2 vs BMI 18-25 kg/m2: serious adverse events | 0 of 29 | 0 of 33 | 62 | NCT01457703 | Trial comparisons |
| Aim 1 vs Aim 2: deaths from any cause | 0 of 13 | 0 of 18 | 31 | NCT02653092 | Trial comparisons |
| Aim 1 vs Aim 2: serious adverse events | 0 of 13 | 0 of 18 | 31 | NCT02653092 | Trial comparisons |
| Obese vs Normal Weight: serious adverse events | 0 of 15 | 0 of 12 | 27 | NCT01894581 | Trial comparisons |
| Experimental vs Control: serious adverse events | 1 of 15 | 0 of 11 | 26 | NCT01381016 | Trial comparisons |
| Younger PMW vs Older PMW: deaths from any cause | 0 of 10 | 0 of 9 | 19 | NCT00386022 | Trial comparisons |
| Younger PMW vs Older PMW: serious adverse events | 0 of 10 | 1 of 9 | 19 | NCT00386022 | Trial comparisons |
| Group 1 (FSH) vs Group 2 (GnRH): deaths from any cause | 0 of 10 | 0 of 6 | 16 | NCT00064987 | Trial comparisons |
| Group 1 (FSH) vs Group 2 (GnRH): serious adverse events | 0 of 10 | 0 of 6 | 16 | NCT00064987 | Trial comparisons |
| Aromatase Inhibitor EFP vs Aromatase Inhibitor LFP: deaths from any cause | 0 of 6 | 0 of 9 | 15 | NCT00351416 | Trial comparisons |
| Aromatase Inhibitor EFP vs Aromatase Inhibitor LFP: serious adverse events | 0 of 6 | 0 of 6 | 12 | NCT00351416 | Trial comparisons |
| Group 1 (FSH) vs Group 2 (GnRH): Fertility | 4 of 4 | 1 of 2 | 6 | NCT00064987 | Trial comparisons |
pipelines-2026-09-18-0.3.1
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL1007/comparisons